ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-Ras, in Patients With Advanced Pancreatic Cancer
Sponsor: Ionis Pharmaceuticals, Inc.
Listed as NCT00005594, this PHASE2 trial focuses on Pancreatic Cancer and remains completed. Sponsored by Ionis Pharmaceuticals, Inc., it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ionis Pharmaceuticals, Inc.
- National Cancer Institute (NCI)
- University of Alabama at Birmingham
For direct contact, visit the study record on ClinicalTrials.gov .